Eton Pharmaceuticals Inc.

12.82
-0.16 (-1.23%)
At close: Apr 01, 2025, 3:05 PM

Company Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases.

The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis.

In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector.

Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc. logo
Country United States
IPO Date Nov 13, 2018
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Sean E. Brynjelsen

Contact Details

Address:
21925 West Field Parkway
Deer Park, Illinois
United States
Website https://www.etonpharma.com

Stock Details

Ticker Symbol ETON
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001710340
CUSIP Number 29772L108
ISIN Number US29772L1089
Employer ID 37-1858472
SIC Code 2834

Key Executives

Name Position
Sean E. Brynjelsen President, Chief Executive Officer & Director
James R. Gruber CPA Chief Financial Officer, Treasurer & Secretary
Danka Radosavljevic Senior Vice President of Quality & Operations
David C. Krempa Chief Business Officer
Ipek Erdogan-Trinkaus Chief Commercial Officer
Kevin Guthrie Executive Vice President of Commercial Operations
Scott Grossenbach Senior Vice President of Sales Operations

Latest SEC Filings

Date Type Title
Mar 18, 2025 8-K Current Report
Mar 18, 2025 8-K Current Report
Mar 18, 2025 10-K Annual Report
Mar 14, 2025 8-K Current Report
Mar 07, 2025 8-K/A [Amend] Current Report
Mar 03, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 07, 2025 8-K Current Report
Feb 06, 2025 8-K Current Report
Jan 06, 2025 4 Filing